Letter to the EditorProfile of serum biomarkers in eosinophilic disorders
Section snippets
Authors' contributions
GH: study design, writing the manuscript, statistics TF: cytokine and chemokine analysis, statistics, MH and KWP: study design, data collection, SKK: critical comments and manuscript revision.
Conflict of interest
The authors declare that they have no conflict of interest.
References (8)
- et al.
Low dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
Blood
(2007) - et al.
High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome
J Allergy Clin Immunol
(2002) - et al.
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes
J Allergy Clin Immunol
(2012) - et al.
Churg-strauss syndrome: evidence for disease subtypes?
Curr Opin Rheumatol
(2010)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.